小剂量沙利度胺联合长春地辛、吡喃阿霉素和地塞米松方案治疗老年多发性骨髓瘤

Low-dose thalidomide combined vindesine,pirarubicin and dexamethasone in the treatment of elderly multiple mydoma

目的分析小剂量沙利度胺联合长春地辛、吡喃阿霉素和地塞米松方案方案，治疗老年多发性骨髓瘤患者临床疗效及不良反应。方法将我院12例老年多发性骨髓瘤患者，进行小剂量沙利度胺联合长春地辛、吡喃阿霉素和地塞米松方案治疗后，进行临床疗效评价及药物不良分析。结果12例不同类型的老年多发性骨髓瘤患者治疗后：完全缓解4例占33．3％，部分缓解5例占41．7％，无效3例占25．0％，总有效率为9例占75．0％。所有患者除有少数出现轻微的头昏、乏力、水肿外，余患者均未发生肝肾功能损害、明显骨髓抑制、神经病变、静脉栓塞等不良反应。结论小剂量沙利度胺联合长春地辛、吡喃阿霉素和地塞米松治疗老年多发性骨髓瘤疗效较好，不良反应轻微，易于耐受。

Objective To analyze the low-dose thalidomide combined vindesine,pirarubicin and dexa- methasone programs programs, treatment of elderly patients with multiple myeloma clinical efficacy and adverse reactions. Methods 12 cases of elderly hospital patients with multiple myeloma, small-dose thalidomide com- bined vindesine,pirarubicin and dexamethasone in the treatment was conducted after the evaluation of clinical efficacy and adverse drug analysis. Results 12 patients with different types of elderly patients with multiple myeloma after treatment：complete remission,4 cases accounted for 33.3% ,partial remission in 5 cases accounted for 41.7% ,3 cases accounted for 25.0% ,with a total effective rate of 9 cases accounted for 75.0%. All patients except a few slight dizziness, fatigue, edema, the liver and kidney function than patients with none of the damage occurred, obviously bone marrow suppression, neuropathy, venous thrombosis and other adverse reactions. Conclusion Low-dose thalidomide combined vindesine, pirarubicin and dexamethasone treatment of multiple myeloma aged better, adverse reactions are mild and easy to tolerate.